Serina Therapeutics Inc (SER) Stock Analysis
Verdict: AVOID
Imminent dilution risk from a 2-month cash runway and -$18M annual burn makes SER an ultra-high-risk speculative trade.
Investment score: 25/100
Analysis as of
Is Serina Therapeutics Inc stock worth reviewing? AI model thesis
The AI model rates SER as AVOID due to urgent cash runway depletion (~2 months remaining) and negative net equity, driving high probability of severe dilution.
7-factor investment score
- Valuation: 15/100 (weight 20%)
- Financial Health: 5/100 (weight 15%)
- Technical Momentum: 45/100 (weight 15%)
- Earnings Quality: 10/100 (weight 15%)
- Insider Sentiment: 55/100 (weight 10%)
- Analyst Consensus: 50/100 (weight 10%)
- Risk-Adjusted Return: 15/100 (weight 15%)
Serina Therapeutics Inc opportunities and risks
What speaks for SER
- POZ platform technology clinical validation
What speaks against SER
- Existential liquidity crisis and severe imminent equity dilution
Frequently asked questions about Serina Therapeutics Inc (SER)
Is SER stock a good investment?
The cached TradeMates AI model rates Serina Therapeutics Inc as AVOID with an investment score of 25/100. The AI model rates SER as AVOID due to urgent cash runway depletion (~2 months remaining) and negative net equity, driving high probability of severe dilution. This is algorithmic model output, not personal investment advice.
Is SER stock a buy?
The TradeMates model verdict for SER is AVOID with an investment score of 25/100. Treat this as a model signal to review, not a personal buy recommendation.